clinical trial · NCT06912295
Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.·phase1·recruiting·n = 76
Healthy ParticipantsHL-1186HL-1186 placebo
brief summary
This single-center, randomized, double-blind, placebo-controlled, two-part study is designed to assess the safety, tolerability and PK of oral HL-1186 Tablet in healthy participants.
started
Mar 21, 2025
primary completion
Aug 30, 2025
completion
Oct 9, 2025
last updated
Aug 24, 2025
official title
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of HL-1186 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol